MiR-4535 and MiR-1915-5p in Amniotic Fluid as Predictive Biomarkers for Chorioamnionitis
URUSHIYAMA Daichi; FUKAGAWA Satoshi; HIRAKAWA Toyofumi; YOSHIKAWA Ken-Ichi; IZUCHI Daisuke; MIYATA Kohei; KURAKAZU Masamitsu; YOTSUMOTO Fusanori; HIROMATSU Kenji; OTA Eiji; HIROSE Shinichi; YASUNAGA Shin'ichiro; MIYAMOTO Shingo
Future Science OA, 2021, Refereed

脂肪組織由来幹細胞を活用した再生医療による着床改善
YOTSUMOTO Fusanori; MIYAMOTO Shingo
産科と婦人科, 2020, Refereed

Clinical Features of Recurrence in Patients Without Residual Tumour in Endometrial Cancer
MIYAMOTO Shingo; YOTSUMOTO Fusanori; MIYAHARA Daisuke; HIRAKAWA Toyofumi; YOSHIKAWA Ken-Ichi; SHIGEKAWA Koichiro; MIYATA Kohei; ITO Tomohiro; KURAKAZU Masamitsu
Anticancer Research, Jul. 2019, Refereed

腹腔鏡下子宮筋腫核出術と開腹子宮筋腫核出術とが及ぼす周産期予後の検討
MIYAMOTO Shingo; KURAKAZU Masamitsu; ITO Tomohiro; IZUCHI Daisuke; YOTSUMOTO Fusanori; MIYAHARA Daisuke
日本産科婦人科内視鏡学会雑誌, 2019

がん性腹膜炎の新規治療
YOTSUMOTO Fusanori; MIYAMOTO Shingo
日本臨床増刊号, 2018

Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer
MIYAMOTO Shingo; IZUCHI Daisuke; FUKAGAWA Satoshi; YOTSUMOTO Fusanori; YOSHIKAWA Ken-Ichi; KIYOSHIMA Chihiro; NAN Son-U; MIYATA Kohei; ITO Tomohiro; KURAKAZU Masamitsu; ARAKI Ryota; SANUI Ayako; MIYAHARA Daisuke; MURATA Masaharu
Anticancer Res, 2018, Refereed

Clinical Significance of Preterm Fetal Cardiotocography in Severe Fetal Acidemia
MIYAMOTO Shingo; ARAKI Ryota; KIYOSHIMA Chihiro; YOTSUMOTO Fusanori; MURATA Masaharu
Med Bull Fukuoka Univ, 2018, Refereed

Microbiome profile of the amniotic fluid as a predictive biomarker of perinatal outcome
MIYAMOTO Shingo; ARAKI Ryota; KIYOSHIMA Chihiro; KURAKAZU Masamitsu; SANUI Ayako; YOTSUMOTO Fusanori; MURATA Masaharu
Scientific Report, 22 Sep. 2017, Refereed

Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer
Kohei Miyata; Fusanori Yotsumoto; Satoshi Fukagawa; Chihiro Kiyoshima; Nam Sung Ouk; Daichi Urushiyama; Tomohiro Ito; Takahiro Katsuda; Masamitsu Kurakazu; Ryota Araki; Ayako Sanui; Daisuke Miyahara; Masaharu Murata; Kyoko Shirota; Hiroshi Yagi; Tadao Takono; Kiyoko Kato; Nobuo Yaegashi; Kohei Akazawa; Masahide Kuroki; ShiN'Ichiro Yasunaga; Shingo Miyamoto
ANTICANCER RESEARCH, Jul. 2017, Refereed

Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy
Satoshi Fukagawa; Fusanori Yotsumoto; Takashi Odawara; Sadao Manabe; Toyokazu Ishikawa; Shin'Ichiro Yasunaga; Shingo Miyamoto
ANTICANCER RESEARCH, Jul. 2017, Refereed

HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFR(T790M)
Fusanori Yotsumoto; Satoshi Fukagawa; Kohei Miyata; Sung Ouk Nam; Takahiro Katsuda; Daisuke Miyahara; Takashi Odawara; Sadao Manabe; Toyokazu Ishikawa; Shin'ichiro Yasunaga; Shingo Miyamoto
ANTICANCER RESEARCH, Jul. 2017, Refereed

MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer
Satoshi Fukagawa; Kohei Miyata; Fusanori Yotsumoto; Chihiro Kiyoshima; Sung Ouk Nam; Haruchika Anan; Takahiro Katsuda; Daisuke Miyahara; Masaharu Murata; Hiroshi Yagi; Kyoko Shirota; Shin'ichiro Yasunaga; Kiyoko Kato; Shingo Miyamoto
CANCER SCIENCE, May 2017, Refereed

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study
MIYAMOTO Shingo; YOTSUMOTO Fusanori; SANUI Ayako
BMC Cancer, 31 Jan. 2017, Refereed

腹膜播種性転移のがん微小環境と分子メカニズム
YOTSUMOTO Fusanori; MIYAMOTO Shingo
先端医療シリーズ48 臨床医のための最新産科婦人科, 2017

Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy
Sung Ouk Nam; Fusanori Yotsumoto; Kohei Miyata; Satoshi Fukagawa; Takashi Odawara; Sadao Manabe; Toyokazu Ishikawa; Masahide Kuroki; ShiN'Ichiro Yasunaga; Shingo Miyamoto
ANTICANCER RESEARCH, Jul. 2016, Refereed

Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma
Kohei Miyata; Fusanori Yotsumoto; Sung Ouk Nam; Takashi Odawara; Sadao Manabe; Toyokazu Ishikawa; Hiroaki Itamochi; Junzo Kigawa; Shuji Takada; Hiroshi Asahara; Masahide Kuroki; Shingo Miyamoto
CANCER MEDICINE, Oct. 2014, Refereed

Pre-clinical Study of BK-UM, a Novel Inhibitor of HB-EGF, for Ovarian Cancer Therapy
Sung Ouk Nam; Fusanori Yotsumoto; Kohei Miyata; Yuki Suzaki; Hiroshi Yagi; Takashi Odawara; Sadao Manabe; Toyokazu Ishikawa; Masahide Kuroki; Eisuke Mekada; Shingo Miyamoto
ANTICANCER RESEARCH, Aug. 2014, Refereed

Possible Therapeutic Targets Among the Molecules Involved in the Warburg Effect in Tumor Cells
Sung Ouk Nam; Fusanori Yotsumoto; Kohei Miyata; Naoto Shirasu; Shingo Miyamoto; Masahide Kuroki
ANTICANCER RESEARCH, Jul. 2013, Refereed

Molecular Hierarchy of Heparin-Binding EGF-like Growth Factor-Regulated Angiogenesis in Triple-Negative Breast Cancer
Fusanori Yotsumoto; Eriko Tokunaga; Eiji Oki; Yoshihiko Maehara; Hiromi Yamada; Kyoko Nakajima; Sung Ouk Nam; Kohei Miyata; Midori Koyanagi; Keiko Doi; Senji Shirasawa; Masahide Kuroki; Shingo Miyamoto
MOLECULAR CANCER RESEARCH, May 2013, Refereed

HB-EGFを標的とした卵巣癌治療薬の創薬.
宮田康平; 南 星旭; 四元房典; 黒木政秀; 宮本新吾
Research, 2013

卵巣がんの腹膜播種に対する新たなアプローチ．
MIYATA Kohei; YOTSUMOTO Fusanori; KUROKI Masahide; MIYAMOTO Shingo
産婦人科の実際, 2013

Clinical significance of amphiregulin and epidermal growth factor in colostrum
Takeshi Nojiri; Toshiyuki Yoshizato; Tatsuya Fukami; Hirotsugu Obama; Hiroshi Yagi; Fusanori Yotsumoto; Shingo Miyamoto
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, Sep. 2012, Refereed

Biological Response Modifiers Used in Cancer Biotherapy
Masahide Kuroki; Shingo Miyamoto; Takashi Morisaki; Fusanori Yotsumoto; Naoto Shirasu; Yoshie Taniguchi; Gen-Ichiro Soma
ANTICANCER RESEARCH, Jun. 2012, Refereed

Regulatory Mechanisms of the HB-EGF Autocrine Loop in Inflammation, Homeostasis, Development and Cancer
Kohei Miyata; Fusanori Yotsumoto; Sung Ouk Nam; Masahide Kuroki; Shingo Miyamoto
ANTICANCER RESEARCH, Jun. 2012, Refereed

Regulatory Mechanisms of the HB-EGF Autocrine Loop in Inflammation, Homeostasis, Development and Cancer
Kohei Miyata; Fusanori Yotsumoto; Sung Ouk Nam; Masahide Kuroki; Shingo Miyamoto
ANTICANCER RESEARCH, Jun. 2012, Refereed

Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737
Kenji Ishitsuka; Naoko Kunami; Hiroo Katsuya; Rumiko Nogami; Chie Ishikawa; Fusanori Yotsumoto; Hiroe Tanji; Naoki Mori; Morishige Takeshita; Shingo Miyamoto; Kazuo Tamura
CANCER LETTERS, Apr. 2012, Refereed

Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer.
Kasai N; Kobayashi K; Shioya S; Yoshikawa Y; Yotsumoto F; Miyamoto S; Mekada E; Enokizono J
Am J Transl Res., 2012, Refereed

HB-EGFを標的とした卵巣癌治療法の開発．
南 星旭; 四元房典; 黒木政秀; 宮本新吾
産婦人科の実際, 2012

婦人科がん－最新の研究動向－ Ⅳ．卵巣がん 卵巣癌の生物学．
四元房典; 黒木政秀; 宮本新吾
日本臨床, 2012

A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Antitumor Mechanisms against Ovarian Cancer Cells
Shingo Miyamoto; Ryo Iwamoto; Akiko Furuya; Kumiko Takahashi; Yuka Sasaki; Hiroshi Ando; Fusanori Yotsumoto; Tomoko Yoneda; Miki Hamaoka; Hiroshi Yagi; Takuya Murakami; Sayaka Hori; Kenya Shitara; Eisuke Mekada
CLINICAL CANCER RESEARCH, Nov. 2011, Refereed

Amphiregulinを標的とした膵癌治療．
四元房典; 深見達弥; 八木裕史; 船越顕博; 吉里俊幸; 黒木政秀; 宮本新吾
日本分子腫瘍マーカー研究会誌, 2011

A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki Ma; Miyamoto S
Anticancer Res., 2011, Refereed

Anti-tumor effects of CRM197, a specific inhibitor for HB-EGF, in T-cell acute lymphoblastic leukemia.
Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki Ma; Miyamoto S
Anticancer Res., 2011, Refereed

Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA.
Hikita S; Yotsumoto F; Fumaki T; Horiuchi S; Sanui A; Miyata K; Nam S; Tsujioka H; Ueda T; Shirota K; Yoshizato T; Maeda K; Ishikawa T; Okuno Y; Kuroki Ma; Mekada E; Miyamoto S
Anticancer Res., 2011, Refereed

Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells
Naohiko Koshikawa; Hiroto Mizushima; Tomoko Minegishi; Fuyuki Eguchi; Fusanori Yotsumoto; Kazuki Nabeshima; Shingo Miyamoto; Eisuke Mekada; Motoharu Seiki
CANCER SCIENCE, Jan. 2011, Refereed

Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki Ma; Miyamoto S
Curr. Opin. Obstet. Gynecol., 2011, Refereed

Apoptosis as a Possible Candidate Mechanism for Removal of Tamoxifen-related Endometrial Cells with KRAS Mutations
Hiroshi Tsujioka; Toru Hachisuga; Shoko Hikita; Taeko Ueda; Fusanori Yotsumoto; Kyoko Shirota; Toshiyuki Yoshizato; Tatsuhiko Kawarabayashi; Masahide Kuroki; Shingo Miyamoto
ANTICANCER RESEARCH, Aug. 2010, Refereed

Emerging Strategies for ErbB Ligand-based Targeted Therapy for Cancer
Hiroshi Tsujioka; Fusanori Yotsumoto; Kyoko Shirota; Shinji Horiuchi; Toshiyuki Yoshizato; Masahide Kuroki; Shingo Miyamoto
ANTICANCER RESEARCH, Aug. 2010, Refereed

卵巣癌におけるHB-EGF特異的抑制剤CRM197とPaclitaxelによる相乗的抗腫瘍効果．
讃井絢子; 八木裕史; 四元房典; 深見達弥; 辻岡 寛; 堀内新司; 黒木政秀; 宮本新吾
日本分子腫瘍マーカー研究会誌, 2010

HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki Ma; Miyamoto S
Int. J. Cancer, 2010, Refereed

HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.
Sanui A; Yotsumoto F; Tsujioka H; Fukami T; Horiuchi S; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki Ma; Miyamoto S
Anticancer Res., 2010, Refereed

Amphiregulin regulates the activation of ERK and Akt through EGFR and HER3 signals involved in the progression of pancreatic cancer.
Yotsumoto F; Fukami T; Yagi H; Funakosi A; Yoshizato T; Kuroki Ma; Miyamoto S
Cancer Sci., 2010, Refereed

Efficacy of Ligand-based Targeting for the EGF System in Cancer
Fusanori Yotsumoto; Ayako Sanui; Tatsuya Fukami; Kyoko Shirota; Shinji Horiuchi; Hiroshi Tsujioka; Toshiyuki Yoshizato; Masahide Kuroki; Shingo Miyamoto
ANTICANCER RESEARCH, Nov. 2009, Refereed

Amphiregulin regulates the production of human chorionic gonadotropin in trophoblasts
Tatsuya Fukami; Toshiyuki Yoshizato; Shingo Miyamoto; Hiroshi Yagi; Fusanori Yotsumoto; Kazuki Nabeshima; Toru Hachisuga; Masahide Kuroki; Tatsuhiko Kawarabayashi
LIFE SCIENCES, Jun. 2009, Refereed

Amphiregulin is much more abundantly expressed than transforming growth factor-alpha and epidermal growth factor in human follicular fluid obtained from patients undergoing in vitro fertilization-embryo transfer
Yoshihito Inoue; Shingo Miyamoto; Tatsuya Fukami; Kyoko Shirota; Fusanori Yotsumoto; Tatsuhiko Kawarabayashi
FERTILITY AND STERILITY, Apr. 2009, Refereed

Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands
Shingo Miyamoto; Tatsuya Fukami; Hiroshi Yagi; Masahide Kuroki; Fusanori Yotsumoto
ANTICANCER RESEARCH, Mar. 2009, Refereed

Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki Ma; Mekada E; Miyamoto S
Int. J. Cancer, 2009, Refereed

HB-EGFとAmphiregulinを標的とした癌治療．
四元房典; 八木裕史; 鈴木 諭; 沖 英次; 辻岡 寛; 蜂須賀徹; 園田顕三; 瓦林達比古; 黒木政秀; 目加田英輔; 宮本新吾
日本分子腫瘍マーカー研究会誌, 2009

卵巣癌におけるHB-EGFによる腹膜播種機構
YOTSUMOTO Fusanori; MIYAMOTO Shingo
Molecular Cancer Therapeutics, 2008, Refereed

HB-EGFとAmphiregulinによる癌標的治療
Fusanorl Yotsumoto; Hiroshi Yagi; Satoshi O. Suzuki; Eiji Oki; Hiroshi Tsujioka; Touru Hachisuga; Kenzo Sonoda; Tatsuhiko Kawarabayashi; Eisuke Mekada; Shingo Miyamoto
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Jan. 2008, Refereed

細胞増殖因子HB-EGFを分子標的とした卵巣癌治療薬の開発．
四元房典; 宮本新吾; 目加田英輔
Bio Clinica, 2008

Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy.
Miyamoto S; Yagi H; Yotsumoto F; Kawarabayashi T; Mekada E
Adv. Exp. Med. Biol., 2008, Refereed

Clinical significance of RCAS1 as a biomarker of ovarian cancer
Kenzo Sonoda; Shingo Miyamoto; Fusanori Yotsumoto; Hiroshi Yagi; Manabu Nakashima; Takeshi Watanabe; Hitoo Nakano
ONCOLOGY REPORTS, Mar. 2007, Refereed

HB-EGFを標的とした癌標的治療
YOTSUMOTO Fusanori; MIYAMOTO Shingo
The Cell, 2007

New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki Ma; Mekada E
Anticancer Res., 2007, Refereed

HB-EGFを標的とした卵巣癌治療薬の創薬.
宮田康平; 南 星旭; 四元房典; 黒木政秀; 宮本新吾
Research, 2013

モデル・コア・カリキュラム対応 医用生化学 ー生体物質の代謝と異常ー ２０１7年版
安永 晋一郎; 黒木 政秀; 黒木 求; 瀬川 波子; 衣笠 哲史; 芝口 浩智; 白須 直人; 四元 房典, Editor, 編著
福岡大学医学部生化学講座, 31 Mar. 2017
9784990942601

モデル・コア・カリキュラム対応 医用生化学 ー生体物質の代謝と異常ー ２０１６年版
安永 晋一郎; 黒木 政秀; 黒木 求; 瀬川 波子; 衣笠 哲史; 芝口 浩智; 白須 直人; 四元 房典, Editor, 編著
福岡大学医学部生化学講座, 31 Mar. 2016
9784990314699

モデル・コア・カリキュラム対応 医用生化学 ー生体物質の代謝と異常ー ２０１５年版
安永 晋一郎; 黒木 政秀; 黒木 求; 瀬川 波子; 衣笠 哲史; 芝口 浩智; 白須 直人; 四元 房典, Joint work, 編著
福岡大学医学部生化学講座, 31 Mar. 2015
9784990314682

モデル・コア・カリキュラム対応 医用生化学―生体物質の代謝と異常― 2014年版
KUROKI Masahide; KUROKI Motomu; SEGAWA Namiko; SHIBAGUCHI Hirotomo; SHIRASU Naoto; YOTSUMOTO Fusanori, Editor
福岡大学医学部生化学教室, 2014
9784990314675

モデル・コア・カリキュラム対応 医用生化学―生体物質の代謝と異常― 2013年版
黒木政秀; 瀬川波子; 芝口浩智; 四元房典; 白須直人, Editor
福岡大学医学部生化学教室, 2013
9784990314668

コアカリキュラム対応 医用生化学―生体物質の代謝と異常― 2012年版．
黒木政秀; 瀬川波子; 芝口浩智; 四元房典; 白須直人, Joint editor
福岡大学医学部生化学教室, 2012

コアカリキュラム対応 人体機能学Ⅲ（生化学）―生体物質の代謝と異常― 2011年版．
黒木政秀; 瀬川波子; 芝口浩智; 四元房典; 白須直人, Joint editor
福岡大学医学部生化学教室, 2011

コアカリキュラム対応 人体機能学Ⅲ（生化学）―生体物質の代謝と異常― 2010年版．
黒木政秀; 瀬川波子; 芝口浩智; 四元房典; 白須直人, Joint editor
福岡大学医学部生化学教室, 2010

コアカリキュラム対応 人体機能学Ⅲ（生化学）―生体物質の代謝と異常― 2009年版．
黒木政秀; 芝口浩智; 四元房典; 白須直人; 瀬川波子, Joint editor
福岡大学医学部生化学教室, 2009

Fusion therapy of cellular and humoral immunity for cancer using antibodies or their genes against carcinoembryonic antigen.
Kuroki Ma; Wang L; Huo Q; Shibaguchi H; Yanagisawa J; Fukami T; Yotsumoto F; Tanaka T; Miyamoto S, Joint work, 233-245
Research Signpost, 2008

シンポジウム 子宮内膜症・子宮筋腫・子宮腺筋症
四元房典
第35回日本女性医学学会学術集会, 21 Nov. 2020

癌治療標的分子RCAS1の発現制御分子の同定
第19回日本婦人科がん分子標的研究会, 14 Nov. 2020

Phase I study on treatment for infertility patients with implantaion failure using autologous adipose tissue derived regenerative cells
Yotsumoto F
第72回日本産科婦人科学会学術講演会, 23 Apr. 2020

MRI画像を用いた成熟嚢胞奇形腫及び内膜症性嚢胞由来の卵巣悪性腫瘍の術前予測の検討
四元房典
第61回日本婦人科腫瘍学会学術講演会, 04 Jul. 2019

成熟囊胞奇形腫及び内膜症性囊胞由来の卵巣悪性腫瘍の MRI 画像診断による術前 予測の検討
四元房典
第71回日本産科婦人科学会学術講演会, 11 Apr. 2019

難治性不妊に対する脂肪組織由来再生細胞を利用した細胞治療
四元房典
第17回日本再生医療学会総会, 21 Mar. 2019

更年期症状の薬物療法と代替療法
四元房典
第268回福岡県病院薬剤師会筑豊支部学術講演会, 20 Feb. 2019

子宮体癌治療の変遷
四元房典
平成30年度第2回子宮がん検診講習会, 31 Jan. 2019

菲薄化子宮内膜による難治性不妊に対する脂肪組織由来再生細胞を利用した治療
四元房典; 城田京子; 伊東裕子; 宮本新吾
第69回日本産科婦人科学会学術講演会, 13 Apr. 2018

着床不全症例に対する脂肪組織由来再生細胞を利用した細胞医療
四元房典
日本生殖再生医学会第12回学術集会, 19 Mar. 2017

胎児染色体異常の予測診断におけるNTと羊膜絨毛膜分離の組み合わせの有用性
四元房典; 吉里俊幸; 荒木陵多; 讃井絢子; 宮本新吾
第68回日本産科婦人科学会学術講演会, 21 Apr. 2016

CD36を標的としたがん治療の創薬開発
四元房典
第2回 新潟産婦人科シンポジウム, 29 Aug. 2015

卵巣癌における予後予測および薬剤感受性に関わるmicroRNA
四元房典; 深川怜史; 宮田 康平; 南 星旭; 安永晋一郎; 黒木政秀; 宮本新吾
第14回日本婦人科がん分子標的研究会学術集会, 17 Jul. 2015

HB-EGF特異的抑制剤CRM197腹腔内投与の抗腫瘍効果の検討．
南 星旭; 四元房典; 宮田康平; 黒木政秀; 宮本新吾
第17回バイオ治療法研究会学術集会, Dec. 2013

卵巣癌における血中HB-EGF濃度と予後の相関．
宮田康平; 四元房典; 南 星旭; 勝田隆博; 前原 都; 宮原大輔; 近藤晴彦; 八木裕史; 小林裕明; 徳永英樹; 高野忠夫; 大槻健郎; 加藤聖子; 八重樫伸夫; 黒木政秀; 宮本新吾
第17回バイオ治療法研究会学術集会, Dec. 2013

上皮系増殖因子 amphiregulinによる結腸癌腫瘍形成における糖代謝の制御．
南 星旭; 四元房典; 宮田康平; 黒木政秀; 宮本新吾
第33回日本分子腫瘍マーカー研究会, Oct. 2013

卵巣がんにおける予後予測マーカーとしての血中 heparin binding epidermal growth factor-like growth factor の意義．
宮田康平; 四元房典; 南 星旭; 植田多恵子; 勝田隆博; 前原 都; 宮原大輔; 近藤晴彦; 八木裕史; 小林裕明; 高野忠夫; 大槻健郎; 加藤聖子; 八重樫伸夫; 黒木政秀; 宮本新吾
第33回日本分子腫瘍マーカー研究会, Oct. 2013

Study on serum HB-EGF as a prognostic biomarker in ovarian cancer patients.
Miyata, K; Yotsumoto, F; Nam, S. O; Yagi, H; Kobayashi, H; Suzuki, F; Takano, T; Kato, K; Yaegashi, N; Kuroki, Ma; Miyamoto, S
第72回日本癌学会学術総会, Oct. 2013

Amphiregulin regulates aerobic glycolysis in tumorigenesis of colorectal cancer.
Nam, S. O; Yotsumoto, F; Miyata, K; Kuroki, Ma; Miyamoto, S
第72回日本癌学会学術総会, Oct. 2013

micro RNA arrayを用いたHB-EGF標的治療反応性の血中マーカーの検索．
MIYATA Kohei; YOTSUMOTO Fusanori; KUROKI Masahide; MIYAMOTO Shingo
第12回日本婦人科がん分子標的研究会, Jul. 2013

大腸癌の分子標的治療法をめざしたAmphiregulinが関与する遺伝子群の解析．
南 星旭; 四元房典; 宮田康平; 黒木政秀; 宮本新吾
第16回バイオ治療法研究会学術集会, 08 Dec. 2012

Enhanced expression of HB-EGF through OxLDL-CD36 pathway in ovarian cancer.
Yotsumoto, F; Nam, S. O; Miyata, K; Yamada, H; Kuroki, Ma; Miyamoto, S
第71回日本癌学会学術総会, 19 Sep. 2012

卵巣癌標的分子HB-EGFの脂質代謝異常関連遺伝子による発現制御機構．
四元房典; 南 星旭; 黒木政秀; 宮本新吾
第16回日本がん分子標的治療学会学術集会, 27 Jun. 2012

卵巣明細胞腺癌の塩酸イリノテカン療法抵抗性におけるHB-EGFの発現機構．
宮田康平; 四元房典; 南 星旭; 板持広明; 紀川純三; 黒木政秀; 宮本新吾
第15回バイオ治療法研究会学術集会, 03 Dec. 2011

Regulation of HB-EGF expression by a transcriptional mechanism contributes to chemoresistance of ovarian clear cell carcinoma.
Miyata K; Yotsumoto F; Nam S. O; Itamochi H; Kigawa J; Kuroki Ma; Miyamoto S
The 39th Meeting of the International Society of Oncology and BioMarkers (ISOBM), 15 Oct. 2011

HB-EGF regulates angiogenesis-related molecules in mammary tumorigenesis.
Nam S. O; Yotsumoto F; Miyata K; Tokunaga E; Akiyoshi, S; Oki E; Maehara Y; Kuroki Ma; Miyamoto S
The 39th Meeting of the International Society of Oncology and BioMarkers (ISOBM), 15 Oct. 2011

Hierarchy of angiogenesis-related molecules involved in tumorigenesis of breast cancer.
Nam S. O; Yotsumoto F; Miyata K; Tokunaga E; Akiyoshi S; Oki E; Maehara Y; Kuroki Ma; Miyamoto S
第70回日本癌学会学術総会, 03 Oct. 2011

Transcriptional regulation in HB-EGF expression contributes to chemoresistance of ovarian clear cell carcinoma.
Miyata K; Yotsumoto F; Nam S. O; Itamochi H; Kigawa J; Kuroki Ma; Miyamoto S
第70回日本癌学会学術総会, 03 Oct. 2011

Possible applications of antibodies or their genes against tumor-associated antigens in cancer diagnosis and therapy.
Kuroki Ma; Yotsumoto F; Choijamts B; Miyamoto S
HSUM International Conference on Medical Molecular Biology, 2011 “From Genomic Research to Cancer Therapy”, 08 Jul. 2011

ジフテリア毒素変異体（CRM197）を用いた卵巣癌標的治療．
疋田祥子; 四元房典; 辻岡 寛; 讃井絢子; 植田多恵子; 城田京子; 堀内新司; 吉里俊幸; 前田一洋; 石川豊数; 奥野良信; 黒木政秀; 宮本新吾
第14回バイオ治療法研究会学術集会, 11 Dec. 2010

卵巣癌標的治療薬ジフテリア毒素変異体（CRM197）の多剤併用療法への応用．
植田多恵子; 辻岡 寛; 深見達弥; 四元房典; 疋田祥子; 高橋庸子; 園田顕三; 小田原隆; 真鍋貞夫; 石川豊数; 黒木政秀; 宮本新吾
第14回バイオ治療法研究会学術集会, 11 Dec. 2010

T細胞性急性リンパ性白血病におけるジフテリア毒素変異体(CRM197)を用いた標的治療．
工並直子; 石塚賢治; 四元房典; 深見達弥; 讃井絢子; 小田原隆; 真鍋貞夫; 石川豊数; 田村和夫; 黒木政秀; 宮本新吾
第14回バイオ治療法研究会学術集会, 11 Dec. 2010

Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma．
Kunami, N; Ishitsuka, K; Yotsumoto, F; Ishikawa, C; Katsuya, H; Sawada, S; Miyamoto, S; Kuroki, Ma; Tamura, K
第69回日本癌学会学術総会, 22 Sep. 2010

Development of molecularly targeted against HB-EGF for proteins with ovarian cancer.
Miyamoto, S; Yotsumoto, F; Kuroki, Ma
第69回日本癌学会学術総会, 22 Sep. 2010

Identification of genes regulating of HB-EGF as a target for breast cancer therapy.
Yotsumoto, F; Kuroki, Ma; Miyamoto, S
第69回日本癌学会学術総会, 22 Sep. 2010

Amphireguilinを標的とした膵癌治療．
四元房典; 深見達弥; 八木裕史; 船越顕博; 吉里俊幸; 黒木政秀; 宮本新吾
第30回日本分子腫瘍マーカー研究会, 21 Sep. 2010

Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of a novel Bcl-2 family inhibitor, ABT-737.
Kunami, N; Ishitsuka, K; Yotsumoto, F; Ishikawa, C; Katsuya, H; Sawada, S; Taniji, H; Takeshita, M; Mori, N; Miyamoto, S; Kuroki, Ma; Tamura, K
101st Annual Meeting of the American Association for Cancer Research (AACR), 17 Apr. 2010

ヒト悪性腫瘍の治療における標的分子としてのHB-EGFとamphiregulinの妥当性．
四元房典
第2回福岡県医学会総会, 31 Jan. 2010

胃癌細胞株における特異的抑制剤CRM197及びPaclitaxelとの相乗的抗腫瘍効果．
讃井絢子; 辻岡 寛; 四元房典; 深見達弥; 堀内新司; 黒木政秀; 宮本新吾
第13回バイオ治療法研究会学術集会, 05 Dec. 2009

HB-EGF as a target molecule for triple negative breast cancer therapy.
Yotsumoto, F; Oki, E; Tokunaga, E; Maehara, Y; Sanui, A; Fukami, T; Kuroki; Ma. Mizushima, H; Mekada, E; Miyamoto, S
第68回日本癌学会学術総会, 01 Oct. 2009

In vitro synergistic antitumor effect of combination of an antibody against amphiregulin and oxaliplatin in colon cancer.
Horiuchi, S; Fukami, T; Tsujioka, H; Yagi, H; Yotusmoto, F; Sanui, A; Kunami, N; Kuroki, Ma; Miyamoto, S
第68回日本癌学会学術総会, 01 Oct. 2009

Anti-tumor effect of CRM197, a specific inhibitor for HB-EGF, in T lymphoblastic leukemia.
Kunami, N; Fukami, T; Yotsumoto, F; Sanui, A; Ishitsuka, K; Tamura, K; Kuroki, Ma; Miyamoto, S
第68回日本癌学会学術総会, 01 Oct. 2009

卵巣癌におけるHB-EGF 特異的抑制剤CRM197 とPaclitaxel による相乗的抗腫蕩効果．
讃井絢子; 八木裕史; 四元房典; 深見達弥; 辻岡 寛; 堀内新司; 黒木政秀; 宮本新吾
第29回日本分子腫瘍マーカー研究会, 30 Sep. 2009

Heparin-binding epidermal growth factor-like growth factor as a target molecule for triple negative breast cancer therapy.
Yotsumoto, F; Oki, E; Tokunaga, E; Maehara, Y; Sanui, A; Fukami, T; Kuroki, Ma; Mizushima, H; Mekada, E; Miyamoto, S
37th Meeting of the International Society of Oncology and BioMarkers (ISOBM), 27 Sep. 2009

In vitro synergistic anti-tumor effect of combination of an antibody against amphiregulin and the anticancer agent oxaliplatin in colon cancer.
Horiuchi, S; Fukami, T; Tsujioka, H; Yagi, H; Yotsumoto, F; Sanui, A; Kunami, N; Kuroki, Ma; Miyamoto, S
37th Meeting of the International Society of Oncology and BioMarkers (ISOBM), 27 Sep. 2009

卵巣癌標的分子HB-EGFのトリプルネガティブ乳癌(TNBC) における標的分子としての妥当性の検討．
四元房典; 沖 英次; 徳永えり子; 前原喜彦; 黒木政秀; 水島寛人; 目加田英輔; 宮本新吾
第8回日本婦人科がん分子標的研究会学術集会, 30 Jul. 2009

卵巣癌におけるパクリタキセルとHB-EGF特異的抑制剤CRM197による相乗的抗腫瘍効果．
讃井絢子; 深見達弥; 四元房典; 宮本新吾
第1回福岡県医学会総会, 25 Jan. 2009

Heparin-binding epidermal growth factor-like growth factor (HB) 特異的抑制剤 CRM197 (CRM) を用いた乳癌標的治療．
四元房典; 沖 英次; 徳永えり子; 前原喜彦; 黒木政秀; 水島寛人; 目加田英輔; 宮本新吾
第12回バイオ治療法研究会学術集会, 06 Dec. 2008

The validation of CRM197, a specific inhibitor for HB-EGF, for molecularly targeted in breast cancer patients．
Yotsumoto, F; Oki, E; Tokunaga, E; Maehara, Y; Kuroki, Ma; Mizushima, H; Mekada, E; Miyamoto, S
第67回日本癌学会学術総会, 28 Oct. 2008

The validation of molecularly targeted therapy against amphiregulin in pancreatic cancer．
Fukami, T; Yagi, H; Yotsumoto, F; Funakoshi, A; Kuroki, Ma; Mekada, E; Miyamoto, S
第67回日本癌学会学術総会, 28 Oct. 2008

HB-EGFとAmphiregulinを標的とした癌治療．
四元房典; 八木裕史; 鈴木 諭; 沖 英次; 辻岡 寛; 蜂須賀徹; 園田顕三; 瓦林達比古; 黒木政秀; 目加田英輔; 宮本新吾
第28回日本分子腫瘍マーカー研究会, 27 Oct. 2008

Phase I sutdy of BK-UK (CRM197) in patients with ovarian cancer.
Miyamoto, S; Yotsumoto, F; Fukami, T; Sanui, A; Kuroki, Ma; Mekada, E
36th Meeting of the International Society of Oncology and BiolMarkers (ISOBM), 05 Oct. 2008

Efficacy of cross-reacting material 197 (CRM197), a specific inhibitor for heparin-binding epidermal growth factor-like growth factor (HB), in breast cancer patients.
Yotsumoto, F; Oki, E; Tokunaga, E; Maehara, Y; Kuroki, Ma; Mizushima, H; Mekada, E. and; Miyamoto, S
36th Meeting of the International Society of Oncology and BiolMarkers (ISOBM), 05 Oct. 2008

The inhibition of amphireguilin blocks AKT as well as ERK activations in pancreatic cancer.
Fukami, T; Yagi, H; Yotsumoto, F; Funakoshi, A; Kuroki; Ma. Mekada; Miyamoto, S
36th Meeting of the International Society of Oncology and BioMarkers (ISOBM), 05 Oct. 2008

Synergistic anti-tumor effects in combination of Gemcitabine with inhibitors for amphiregulin.
Fukami, T; Yagi, H; Yotsumoto, F; Funakoshi, A; Kuroki, Ma; Mekada, E; Miyamoto, S
99th Annual Meeting of the American Association for Cancer Research (AACR), 12 Apr. 2008

Heparin-binding epidermal growth factor-like growth factor (HB) regulates mammary tumorigenesis through EGFR as well as Her2 signal.
Yotsumoto, F; Yagi, H; Fukami, T; Kuroki, Ma; Mizushima, H; Mekada, E; Miyamoto, S
99th Annual Meeting of the American Association for Cancer Research (AACR), 12 Apr. 2008

ヒト膵臓癌標的分子amphiregulinの妥当性とamphiregulin抑制剤の治療への応用の可能性．
深見達弥; 八木裕史; 四元房典; 船越顕博; 黒木政秀; 目加田英輔; 宮本新吾
第11回バイオ治療法研究会学術集会, 01 Dec. 2007

Synergistic anti-tumor effects of CRM197 and paclitaxel in patients with advanced gastric cancer.
Miyamoto, S; Yagi, H; Yotsumoto, F; Fukami, T; Kuroki, Ma; Mekada, E
第66回日本癌学会学術総会, 03 Oct. 2007

Amphiregulin enchances drug-resistance for pancreatic and colon cancers.
Fukami, T; Yagi, H; Yotsumoto, F; Oki, E; Kuroki, Ma; Mekada, E; Miyamoto, S
第66回日本癌学会学術総会, 03 Oct. 2007

HB-EGF or amphiregulin is a promising target for human cancer therapy.
Yotsumoto., F; Yagi. H; Sonoda, K; Tsujioka, H; Hachisuga, T; Kawarabayashi, T; Oki, E; Kuroki, Ma; Mekada, E; Miyamoto, S
第66回日本癌学会学術総会, 03 Oct. 2007

Heparin-binding epidermal growth factor-like growth factor (HB) とamphiregulin (AR)を標的とした癌治療．
四元房典; 八木裕史; 園田顕三; 辻岡筧; 蜂須賀徹; 瓦林達比古; 沖 英次; 黒木政秀; 目加田英輔; 宮本新吾
第6回日本婦人科がん分子標的研究会学術集会, 21 Jul. 2007

卵巣癌腹膜におけるHeparin binding epidermal growth factor-like growth factor (HB)の役割．
八木裕史; 四元房典; 深見達弥; 瓦林達比古; 目加田英輔; 宮本新吾
第6回日本婦人科がん分子標的研究会学術集会, 21 Jul. 2007

卵巣癌におけるHB-EGFとタキソールとの関連．
深見達弥; 八木裕史; 四元房典; 瓦林達比古; 目加田英輔; 宮本新吾
第6回日本婦人科がん分子標的研究会学術集会, 21 Jul. 2007

HB-EGF(HB)を標的とした卵巣癌治療の医師主導型治験．
宮本新吾; 八木裕史; 四元房典; 深見達弥; 吉里俊幸; 堀内新司; 瓦林達比古; 目加田英輔
第6回日本婦人科がん分子標的研究会学術集会, 21 Jul. 2007

The Japanese Cancer Association

Japan Society of Obstetrics and Gynecology

HB-EGF発現を制御する転写因子の同定と癌の診断及び治療への応用
文部科学省若手研究B
2010 - 2011

HB-EGF発現制御機構に関する研究
福岡大学研究推進部領域別研究チーム
2009 - 2011

癌標的分子HB-EGFの発現制御機構に関する分子の探索
財団法人臨床研究奨励基金
2009